Company news: Eli Lilly

Share this article:
Eli Lilly said it is halting development of one of two phase III Alzheimer's disease drugs in its pipeline. Two studies involving semagacestat, a gamma secretase inhibitor, are being stopped because semagacestat patients did worse than placebo on clinical measures of cognition and the ability to perform activities of daily living; patients also seemed to have a higher incidence of skin cancer. Lilly said that the second drug, monoclonal antibody solanezumab, has a different mechanism of action and that clinical trials are ongoing. Two other early-stage Alzheimer's drugs are unaffected. The news, combined with Lilly's recent loss in a patent suit involving the ADHD drug Strattera, darkened the outlook for the company. Five of its biggest sellers are set to lose patent protection by 2013, including Strattera, although Lilly is seeking a court order temporarily blocking US launch of generic versions of that drug.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.